Docetaxel for the post-surgery treatment of patients with node-positive breast cancer

Adjuvant chemotherapy reduces risk of relapse and cancer-related mortality in early stage breast cancer. Over the last decade, taxanes (paclitaxel and docetaxel) have been incorporated into various adjuvant trials and have demonstrated a significant benefit in the management of early stage breast ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Pant, Shubham, Chilukuri, Meena P, Ramaswamy, Bhuvaneswari
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2504077/
https://www.ncbi.nlm.nih.gov/pubmed/18728853
_version_ 1782158358221946880
author Pant, Shubham
Chilukuri, Meena P
Ramaswamy, Bhuvaneswari
author_facet Pant, Shubham
Chilukuri, Meena P
Ramaswamy, Bhuvaneswari
author_sort Pant, Shubham
collection PubMed
description Adjuvant chemotherapy reduces risk of relapse and cancer-related mortality in early stage breast cancer. Over the last decade, taxanes (paclitaxel and docetaxel) have been incorporated into various adjuvant trials and have demonstrated a significant benefit in the management of early stage breast cancer. Clinical trials using combinations of taxanes with targeted therapy have also shown considerable activity in breast cancer. This article reviews the pharmacology of docetaxel, a semi-synthetic taxane, and the clinical trials supporting its use in patients with node-positive breast cancer.
format Text
id pubmed-2504077
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-25040772008-08-26 Docetaxel for the post-surgery treatment of patients with node-positive breast cancer Pant, Shubham Chilukuri, Meena P Ramaswamy, Bhuvaneswari Ther Clin Risk Manag Review Adjuvant chemotherapy reduces risk of relapse and cancer-related mortality in early stage breast cancer. Over the last decade, taxanes (paclitaxel and docetaxel) have been incorporated into various adjuvant trials and have demonstrated a significant benefit in the management of early stage breast cancer. Clinical trials using combinations of taxanes with targeted therapy have also shown considerable activity in breast cancer. This article reviews the pharmacology of docetaxel, a semi-synthetic taxane, and the clinical trials supporting its use in patients with node-positive breast cancer. Dove Medical Press 2008-04 2008-04 /pmc/articles/PMC2504077/ /pubmed/18728853 Text en © 2008 Dove Medical Press Limited. All rights reserved
spellingShingle Review
Pant, Shubham
Chilukuri, Meena P
Ramaswamy, Bhuvaneswari
Docetaxel for the post-surgery treatment of patients with node-positive breast cancer
title Docetaxel for the post-surgery treatment of patients with node-positive breast cancer
title_full Docetaxel for the post-surgery treatment of patients with node-positive breast cancer
title_fullStr Docetaxel for the post-surgery treatment of patients with node-positive breast cancer
title_full_unstemmed Docetaxel for the post-surgery treatment of patients with node-positive breast cancer
title_short Docetaxel for the post-surgery treatment of patients with node-positive breast cancer
title_sort docetaxel for the post-surgery treatment of patients with node-positive breast cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2504077/
https://www.ncbi.nlm.nih.gov/pubmed/18728853
work_keys_str_mv AT pantshubham docetaxelforthepostsurgerytreatmentofpatientswithnodepositivebreastcancer
AT chilukurimeenap docetaxelforthepostsurgerytreatmentofpatientswithnodepositivebreastcancer
AT ramaswamybhuvaneswari docetaxelforthepostsurgerytreatmentofpatientswithnodepositivebreastcancer

Ejemplares similares